Manipal Health Enterprises Ltd (MANIPALHOS) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch
Manipal Health Enterprises runs one of India's largest hospital networks — 50 hospitals with over 13,400 licensed beds across 14 States & Union Territories — and Q2 FY 2026-2027 is its first full quarter as a listed company after the August 2026 IPO. The print will speak to two big things: whether the ex-Sahyadri margin dip of 1.5% YoY normalises as management has guided, and how much of the finance-cost relief from the September 17-18, 2026 redemption of Rs. 5,310 Cr NCDs flows into this quarter.
| Results date | November 13, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 3,090.6 Cr |
| Previous quarter PAT | Rs. 243.4 Cr |
| Previous quarter EBITDA margin | 24.2% |
| Market cap | Rs. 85,065.44 Cr |
| CMP | Rs. 646.7 |
Manipal Health Enterprises Ltd Q2 Results Date and Time
The Board is scheduled to meet on November 13, 2026 to approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, with the statutory auditors' limited review report.
An earnings call is scheduled for Friday, November 13, 2026, from 18:00 to 19:00 IST, following the Q2 FY27 and H1 FY27 results. It will feature MD & CEO Dilip Jose, Group CFO Sameer Agarwal and COO Karthik Rajagopal.
No dividend was recommended for FY 2025-26, per the AGM notice and FY26 annual report disclosures.
What to expect from Manipal Health Enterprises Ltd's Q2 FY27 results
The quarter's biggest swing factor is finance cost: the Rs. 8,000 Cr IPO (listed August 5, 2026) funded the September 17-18, 2026 redemption of Rs. 5,310 Cr listed NCDs, but since the redemption landed in the final two weeks of the quarter, Q2 should step down from Q1's Rs. 293.3 Cr finance cost while still carrying most of the pre-redemption debt load, with the full run-rate benefit a Q3 phenomenon.
Management guided net debt/EBITDA to 0.9x by Q2 FY27 from 2.8x, and reported-versus-adjusted PAT will again be a watch point after Q1 carried Rs. 89 Cr of post-tax Sahyadri NCD interest and Rs. 15.5 Cr of exceptional items.
On operations, Q1 growth was volume-led — IP volumes up 38.8% YoY at 155k, OP volumes up 26.0%, occupancy 65.0% (+290 bps YoY) — with core ex-Sahyadri revenue growth of 23% that management called 'secular tailwinds, not one-offs', and the Electronic City ~300-bed facility (the network's 50th hospital, commenced July 2026) contributing its first partial quarter within the ~1,000-bed FY27 addition plan.
On margins, management's Q1 bridge attributed the ex-Sahyadri step-down from 26.5% to 25.0% to three temporary items — a 0.6% one-off base effect, ~0.5% greenfield doctor costs at Kanakapura and Yelahanka, and slower scheme-patient collections — with Sahyadri guided from 17-17.5% toward the ~25% portfolio average in coming quarters and greenfield margins (13% in Q1) improving over the next 1-1.5 years.
A fresh regulatory overhang sits on the consumable-billing line: the Centre ordered an NPPA report on surgical-consumable markups on September 17, 2026 and the Department of Pharmaceuticals began consultations with private hospitals on September 19-20, 2026, though nothing was finalised inside the quarter. The upcoming call is likely to cover bed execution (Raipur in Q4 FY27, Kinder timing), the 0.9x leverage confirmation, margin normalisation and the ARPOB mix effect, where reported ARPOB grew only 0.7% YoY versus 8.7% ex-Sahyadri at Rs. 77,200/day.
Key Things To Watch
Performance vs Guidance Tracking: Management reaffirmed bed additions as on track; here is the guidance scorecard to test on the call.
- Bed additions — ~1,000 beds by FY27 — on track per Group CFO, with Electronic City ~300 beds slated for Q2 FY27 (50th hospital commenced July 2026) and Raipur commissioning in Q4 FY27
- Capex — ~Rs. 2,000 Cr by FY27 with Rs. 900 Cr already spent in Q1; ~Rs. 4,000 Cr over 3-4 years tied to the 3,000-bed program
- Net debt/EBITDA — 0.9x by Q2 FY27 (from 2.8x) after the Rs. 5,310 Cr NCD redemption completed September 17-18, 2026
- Sahyadri EBITDA margin — improve closer to the portfolio average in coming quarters, from 17-17.5% vs the ex-Sahyadri network's ~25%
- Kinder remodel into a multi-specialty hospital within 6-7 months, with facility transfer within 60 days after conditions are met
Margin normalisation and Sahyadri trajectory
- Whether the ~0.5% greenfield doctor-cost drag (Kanakapura/Yelahanka) and the scheme-patient collection drag reverse as management flagged temporary, and whether ex-Sahyadri margins hold at ~25%
- Sahyadri margin progress toward the portfolio average, integration milestones within the 16-18 month plan, and occupancy recovery from the 100 bps YoY dip to 62.6%
- ARPOB mix effect: reported ARPOB grew only 0.7% YoY vs 8.7% ex-Sahyadri (Rs. 77,200/day), with Sahyadri's case-mix uplift from Rs. 44,800/day to monitor
Finance cost, leverage and reported vs adjusted PAT
- Q2 finance cost versus Q1 FY27's Rs. 293.3 Cr, given the NCD redemption landed only in the quarter's final two weeks (September 17-18)
- Confirmation of the 0.9x net debt/EBITDA guide at Q1-level EBITDA and the post-redemption interest burden on reported PAT
Strategic execution: Kinder, Juhu and Gurugram
- Kinder Women's Hospital (Whitefield, Rs. 130 Cr BTA, 100 beds): transfer expected within 60 days after conditions are met, remodel into a multi-specialty hospital within 6-7 months
- Juhu (Mumbai) greenfield: Rs. 495 Cr land-and-building acquisition (Rs. 365 Cr paid, Rs. 130 Cr payable subject to conditions)
- Gurugram lease announced November 4, 2026: ~3.5 acres from Thakral's TIL Investments, initial lease ~30 years, first phase up to 500 beds
Risks and regulatory follow-ups
- GST appeals on subsidiary Manipal Hospitals Eastern India: two demands totalling ~Rs. 8.00 Cr plus ~Rs. 4.61 Cr penalties (FY 2019-20 and FY 2021-22); company stated no material impact and is appealing
- 100% of the 27.70% promoter holding (36,90,38,332 shares) remains encumbered, including a fresh October 24, 2026 pledge on 1,44,92,951 shares (1.09%) for Claypond Capital's unlisted NCDs of up to Rs. 500 Cr
- Status of the NPPA/DoP consumable-markup review (NPPA report ordered September 17, 2026; DoP consultations September 19-20, 2026) touching the consumable-billing revenue line
Ask about this
Ask Cofacto a question about this company. Answers cite filings and company data.
Frequently Asked Questions
Why did Manipal Hospitals' ex-Sahyadri margin dip in Q1 FY27?
The ex-Sahyadri margin fell from 26.5% in Q1 FY26 to 25.0% in Q1 FY27, a 1.5% dip. Management attributed it to a 0.6% one-off base effect, ~0.5% of greenfield doctor costs at Kanakapura and Yelahanka, and slower scheme-patient collections, and called all three temporary.
How much debt is Manipal Hospitals comfortable carrying after its IPO?
Management guided net debt/EBITDA down to 0.9x by Q2 FY27 from 2.8x after the September 17-18, 2026 redemption of Rs. 5,310 Cr listed NCDs, and said it is comfortable operating at 1.5-2x EBITDA. The deleveraged balance sheet supports a plan of 3,000 beds over 3-4 years with ~Rs. 4,000 Cr of capex.
Is Manipal Hospitals on track with its ~1,000-bed FY27 bed addition guidance?
Group CFO Sameer Agarwal confirmed the ~1,000-bed FY27 target is on track, with the 103-bed Nashik brownfield commissioned in Q1 and the 300-bed 50th hospital launched at Electronic City, Bengaluru in July 2026. He also indicated Kinder beds could come over and above the committed additions.
When will Sahyadri Hospitals' margins catch up with the rest of the Manipal network?
Sahyadri's EBITDA margin was 17-17.5% in Q1 FY27 versus the ex-Sahyadri network's ~25%, and management has guided it to move closer to the portfolio average in the coming quarters. The playbook of doctor interoperability, case-mix uplift and conversion efficiencies drove initial revenue growth of over 13% and EBITDA growth of 19-20%.
Related
Disclaimer: This earnings preview is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.